Analyses of 40 kDa peginterferon alfa-2A (Pegasys®) in combination with ribavirin, mycophenolate mofetil, amantadine, or amantadine plus ribavirin in patients that relapsed or did not respond to rebetron™ therapy: a report of two randomized, multicenter, efficacy and safety studies: Nezam Afdhal, Beth Israel Deaconess Medical Ctr, Boston, MA; Steven Flamm, Northwestern Memorial Hospital, Chicago, IL; Joanne C Imperial, Stanford University School of Medicine, Palo Alto, CA; Peter F Malet, University of Texas Southwestern Medical Center, Dallas, TX; Myron Tong, Hungtington Hospital Liver Center, Pasadena, CA; Steven K Herrine, Thomas Jefferson University Hospital, Philadelphia, PA; Robert Brown Jr., Columbia Presbyterian Medical Center, New York, NY; Stephen Esposito, Hepatobiliary Associates of New York, Bayside, NY; David E Bernstein, North Shore University Hospital, Manhasset, NY; Jennifer L Campagna, Roche Laboratories Inc, Nutley, NJ